N/A N=5,012 HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
HIV/AIDS · Sexually Transmitted Infections
Primary: STI Incidence — 250; 226 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
N/A N=175 Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America
HIV Infection · Human Immunodeficiency Virus 1 Positive · Malignant Neoplasm
Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…
Phase 2 N=12 Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
Phase 2 N=34 AIDS 347: IL-6 Blockade in Treated HIV Infection
HIV Infections
Primary: Number of Grade 2 or Greater AEs — 10; 2 Participants — p=0.07
Phase 4 N=1,771 Antiretroviral Therapy for Advanced HIV Disease in South Africa
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
N/A N=106 Secondary HIV Prevention and Adherence Among HIV-infected Drug Users
Risk Behavior · Medication Adherence · HIV
Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants
N/A N=216 Treatment Advocacy Intervention for HIV-Positive African Americans
HIV
Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005
N/A N=28 Youth Ending the HIV Epidemic
HIV/AIDS · Mobile Health · Young Adults
Primary: Feasibility: Rate of Participant Retention — 22 Participants
N/A N=7 Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
HIV Infections
Primary: Rate of Medication Adherence — 2; 1 Participants
N/A N=37 Cardiovascular Prevention for Persons With HIV
HIV Infection · Cardiovascular Disease Risk
Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants
N/A N=143 Pain and Sensory Changes Assessment in HIV+ Patients
HIV Infections
Primary: Number of Participants With Chronic Myogenic Pain, TMJ Disoder, and Burning Mouth Syndrome — 72; 8; 37; 7 Participants
Phase 2 N=121 Modulation of Immune Activation by Aspirin
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 11/12 — 0.99; 1.03; 0.97 fold change — p=0.70
N/A N=512 Adherence Support Intervention for Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia
HIV · AIDS · Medication Adherence
Primary: Antiretroviral Therapy (ART) Adherence (Self-reported 3-day Recall Measure) — 142; 139; 6; 12 participants
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
N/A N=223 Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences
HIV Infections
Primary: Neuropsychological Status (i.e., Cognitive Functioning) — 0.008; .484; -.084; -.482 z-score composites of cognitive domains — p=0.001
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
N/A N=250 Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
Phase 3 N=192 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
HIV-1 Infection · Kaposi's Sarcoma
Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911
Phase 2 N=594 Improving Treatment Adherence in HIV-Infected Individuals
HIV Antiretroviral Therapy (ART) Adherence · Health Behavior
Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12
N/A N=121 Living Well Project for Persons With AIDS
Acquired Immunodeficiency Syndrome (AIDS)
Primary: Change in Quality of Life — 5.87; 5.17; 5.68; 5.06 score on a scale
Phase 3 N=3,556 Preventing Sexual Transmission of HIV With Anti-HIV Drugs
HIV Infections
Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001
N/A N=219 HIV-Tb Confections Among HIV Patients
HIV
Primary: Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center. — 48 participants
Phase 2 N=43 Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…
Phase 2 N=177 Staying Well: A Clinical Trial of Mindfulness-Based Stress Reduction and Education Groups for HIV
HIV
Primary: Change in CD4 T-cell Count — -57.1; -70.3 cells/µl
N/A N=172 Durability of Adherence in Self-Management of HIV
HIV Infections
Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52
N/A N=328 Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
HIV Infection
Primary: Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT) — 8.2; 10.7; 12.9 micron/year — p=0.013
Phase 4 N=108 SSRI Effects on Depression and Immunity in HIV/AIDS
Depression · HIV · AIDS
Primary: Natural Killer Cell Activity, Measured in Lytic Units [Bryant J, Day R, Whiteside TL, and Herbeman RB: Calculation of Lytic Units for the Expression of Cell-mediated…
Phase 1 N=18 Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
Distress · Depression · Grief
Primary: Number of Participants Who Experienced Treatment-related Adverse Events as Assessed by NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse…
Phase 3 N=16,395 HIV Vaccine Trial in Thai Adults
HIV Infection
Primary: Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat Population — 0.15; 0.38; 0.41; 0.64 Percetage of subjects